Cardiovascular System
The pump and plumbing. A muscle that beats three billion times pushes blood through 60,000 miles of vessels to every cell you own.
The cardiovascular system is a closed loop — a four-chambered pump driving blood through arteries, capillaries, and veins, and then back again. Its job is to deliver oxygen and nutrients, clear carbon dioxide and metabolic waste, distribute hormones, and move heat. When it fails, nothing else gets to run.
At a glance
What it does
Moves blood. That is the whole trick, and it is harder than it sounds. Blood carries oxygen bound to hemoglobin, glucose and fat for fuel, electrolytes for signaling, immune cells, hormones, clotting factors, and waste. Stop the pump for four minutes and neurons start dying. Every other system on this site assumes this one is working.
How it works
The right side of the heart collects deoxygenated blood from the body and pumps it to the lungs. The left side collects oxygenated blood from the lungs and pumps it to the body. Arteries carry high-pressure oxygenated blood out; veins bring low-pressure deoxygenated blood back. Capillaries are where the actual exchange with tissue happens, and they are one cell thick by design.
Output is heart rate times stroke volume. Both are modulated by sympathetic drive (up) and parasympathetic tone (down). Arterial pressure is maintained by a mix of cardiac output, peripheral vascular resistance, and blood volume — and regulated by the renin-angiotensin-aldosterone system in the kidneys, along with vasopressin from the pituitary.
Vessels and circulation
Arteries have thick muscular walls to handle pressure; small arteries (arterioles) are where most of the resistance lives, and tiny changes in their tone swing blood pressure hard. Capillaries have almost no wall — just a single endothelial layer — so oxygen, CO2, and small solutes can diffuse across. Venous return to the heart relies on valves, skeletal muscle contraction, and respiratory pressure changes; this is why sitting perfectly still for hours is genuinely bad for you.
When it goes wrong
Cardiovascular disease is the leading cause of death globally and in almost every country with records. Atherosclerosis — cholesterol plaques building inside artery walls over decades — narrows vessels and can rupture, triggering heart attacks and strokes. Hypertension (blood pressure chronically over roughly 130/80) damages vessels and heart muscle silently for years before anything visible fails.
Heart failure is the endgame of chronic damage: the pump weakens, fluid backs up into lungs and tissues, exercise becomes impossible. Arrhythmias range from benign to lethal depending on which chambers misfire. Venous thromboembolism (clots in deep veins that can migrate to lungs) kills by the tens of thousands yearly and is strongly linked to immobility, recent surgery, hormonal contraception with estrogen, and certain cancers.
Interactions
Cortisol and chronic sympathetic activation raise blood pressure and damage endothelium. Insulin resistance wrecks vessel wall biology and tracks closely with atherosclerosis. Estrogen is vasoprotective, which is part of why premenopausal women have lower CV risk than age-matched men. Exercise — specifically zone 2 cardio plus some high-intensity work — improves nearly every measurable CV parameter, more reliably than most drugs.
Honest take
Cardiovascular medicine is the clearest example of lifestyle beating late-stage pharmacology on prevention and pharmacology beating lifestyle on rescue. If you are under 50 with no events, the payoff from fitness, blood pressure, apoB, and not smoking dwarfs anything else you can do. After a first event, you want a statin, a blood pressure drug, and low-dose aspirin, and arguing about it is how people end up with second events. LDL is not the "bad cholesterol" — apoB is the particle count that actually causes the disease, and every major trial lowering it lowers events.
Sources
- Braunwald's Heart Disease, 12th ed. — the reference textbook of cardiology.
- Ference et al. (2017), JACC — Mendelian randomization confirming causal role of LDL/apoB in ASCVD.
- Sabatine et al., NEJM — PCSK9 inhibitor trials showing event reduction proportional to LDL lowering even at extreme lows.